Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Primary lung cancer is the most common malignancy after nonmelanocytic skin cancer with
deaths from lung cancer exceeding those from any other type of malignancy worldwide [1] …

Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …

Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …

Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …

According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …

Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …